Seeking Alpha

Moody's raises Celgene's (CELG) outlook to Positive from Stable citing the "expanding use of...

Moody's raises Celgene's (CELG) outlook to Positive from Stable citing the "expanding use of Revlimid" (I, II) and "pending approvals of Apremilast in psoriatic arthritis and Abraxane in pancreatic cancer" (I, II) as catalysts for "good growth momentum."
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|